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Abstract In skeletal muscle, neuronal nitric oxide synthase is
localized at the sarcolemma in association with the dystrophin
glycoprotein complex (DGC). The nNOS N-terminal 231 amino
acids comprise a PDZ domain (residues 1^100) and a L-hairpin
finger loop (residues 101^130) which binds K-syntrophin located
in the DGC. Endogenous nNOS and GFP-tagged nNOS localize
to the sarcolemma in mouse C2C12 myotubes. Expression of
GFP-tagged nNOS domains in C2C12 myotubes reveals that the
PDZ domain and the L-hairpin finger loop of nNOS are
independently capable of localizing to the sarcolemma of C2C12
myotubes. Binding studies indicate that K-syntrophin binds only
to the L-hairpin finger loop and not the PDZ domain of nNOS.
nNOS may bind to proteins in addition to K-syntrophin at muscle
sarcolemma. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The neuronal isoform of nitric oxide synthase (nNOS) is
highly expressed in skeletal muscle [1,2] where it is co-local-
ized to the sarcolemma with the dystrophin glycoprotein com-
plex (DGC) [3]. Association of nNOS with the DGC accounts
for its unique sarcolemmal localization in skeletal muscle ¢-
bers observed in the immunostaining patterns in cross-sections
of skeletal muscle tissues [1,3]. The signaling role of nNOS in
skeletal muscle is poorly understood; however in skeletal
muscles isolated from mice lacking nNOS, the contraction-
stimulated NO production and subsequent cGMP formation
signaling pathway is compromised but with no detectable sign
of muscle pathology [4].
nNOS is unique among the di¡erent nitric oxide synthases
in that it possesses an additional 231 amino acid N-terminal
extension that interacts with the PDZ domain of K-syntro-
phin, a 58 kDa protein member of the plasma membrane-
associated DGC [5,6]. PDZ domains are characterized by
their ability to interact with other proteins to form organized
complexes required for diverse signaling pathways and protein
interactions take place predominantly through recognition of
short consensus carboxyl-terminal peptide motifs, which bind
to the consensus peptide binding groove present in PDZ do-
mains. The N-terminal 100 amino acids of nNOS also contain
a PDZ domain. The crystal structure of the ¢rst 300 amino
acids of nNOS bound to the PDZ domain of K-syntrophin
depicts a unique L-hairpin ¢nger loop located between resi-
dues 100^130 of nNOS which interacts directly with the can-
onical peptide groove of the PDZ domain of K-syntrophin
leaving the peptide binding groove of the PDZ domain of
nNOS available for other protein interactions [7].
Disruption of the DGC as in the dystrophin-de¢cient mdx
mice results in the absence of nNOS sarcolemmal localization
[3,4] in addition to loss of nNOS signaling function [8]. More-
over, in mice lacking K-dystrobrevin (dbn3=3) most of the
DGC proteins remain intact at the sarcolemma including
K-syntrophin [9]. However nNOS and contraction-stimulated
cGMP formation are attenuated in skeletal muscles isolated
from dbn3=3 mice [9]. Despite the essentially intact nature of
the DGC observed in dbn3=3 mice, they exhibit skeletal
muscle and cardiac myopathy. The precise interactions of
nNOS with the DGC at the sarcolemma of skeletal muscle
are unclear.
In mouse C2C12 myoblasts, dystrophin and many other
components of the DGC are not detectable. However as the
C2C12 cells fuse to form myotubes, dystrophin is expressed
and is localized to myotube tips, Triton X-100-insoluble cyto-
skeleton and costameres [10]. Other members of the DGC are
also expressed and co-localized with dystrophin in di¡erenti-
ated C2C12 myotubes including aciculin [10], K-dystroglycan
[11], L-dystroglycan [12] and the members of the sarcoglycan
complex [13]. In this study we use di¡erentiated mouse C2C12
myotubes to investigate the nNOS determinants that account
for the co-localization of nNOS at the sarcolemma in skeletal
muscle. Results suggest multiple binding partners exist for
nNOS at the sarcolemma where independent binding exists
for both the PDZ domain and the L-hairpin ¢nger loop of
nNOS.
2. Materials and methods
Chemicals and biochemicals were purchased from Sigma. Mouse
C2C12 cell line was purchased from ATCC. DMEM, cell culture
reagents and molecular biology reagents were purchased from GIB-
CO-BRL, MD, USA. Mouse anti-GFP monoclonal antibody was
purchased from Zymed Labs., CA, USA. Rhodamine-red goat anti-
rabbit was purchased from Molecular Probes, USA. GST-Sepharose
was purchased from Amersham-Pharmacia, UK.
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2.1. Cell culture
COS-7 cells were grown and maintained in Dulbecco’s modi¢ed
essential medium (DMEM) and 10% fetal bovine serum in 35 mM
culture dishes. Mouse C2C12 myoblast cells were grown on 150 mm
dishes in growth media composed of DMEM and 10% fetal bovine
serum. All cells were maintained in a humidi¢ed incubator at 37‡C
and 95% air^5% CO2. Cells were fed every 2 days.
2.2. Di¡erentiation of C2C12 cells
C2C12 myoblasts were di¡erentiated into myotubes using HIT me-
dium (DMEM containing 2% heat-inactivated horse serum, 10 Wg/ml
transferrin and 10 Wg/ml insulin). The media were changed every 48 h.
2.3. Electroporation of C2C12 myoblasts
C2C12 myoblasts 70^80% con£uent were harvested by trypsiniza-
tion and resuspended in 5 ml of growth media and diluted to a con-
centration of 2U107 cells per ml. For transfection, 107 cells (0.5 ml)
were mixed with 10 Wg of plasmid and 120 Wg of sheared salmon
sperm DNA in a 0.4 cm electroporation cuvette. Electroporation
was performed under the following conditions: voltage, 300 V, resis-
tance, R5 and capacitance, 1150 WF. Following electroporation, cells
were immediately transferred to 35 mm culture plates containing 4 ml
of growth media plus 1% butyrate. Each 35 mm plate had a glass
coverslip. Transfected cells were cultured for 24 h after which the
media was aspirated and replaced with 4 ml of growth media (control
cells) or 4 ml HIT di¡erentiation media (for di¡erentiation of myo-
blasts into myotubes). Cells were maintained as before and media
were changed every 48 h.
2.4. Construction of nNOS-GFP plasmids
Fragments of rat nNOS cDNA [14] were ampli¢ed by polymerase
chain reaction (PCR) using Expand-PCR (Roche Biochemicals). Re-
action mixtures contained the cDNA for the full length rat nNOS
(FL-nNOS) as a template and oligonucleotide primer pairs. The fol-
lowing primer pairs (sense/antisense) were synthesized to produce
cDNA fragments that encoded nNOS amino acid residues shown
in parentheses: 5P-AGAATTCATATGGAAGAGAACACG-3P/5P-C-
GCACTAGTAGGGCCCCTCAGAATGAG-3P (1^100), 5P-AGA-
ATTCATATGGAAGAGAACACG-3P/5P-CGCACTAGTGCTTTT-
CATCTC-3P (1^231), 5P-TAGAATTCATATGAGGGCTTCACTA-
CA-3P/5P-CGCACTAGTGCTTTTCATCTC-3P (101^231), 5P-TAGA-
ATTCATATGGGAATCCAGGTGGACAGA-3P/5P-CGCACTAGT-
GGAGCTGAAAACCTC-3P (232^1429), 5P-AGAATTCATATGG-
AAGAGAACACG-3P/5P-CGCACTAGTGGAGCTGAAAACCTC-
3P (1^1429). After incubation at 94‡C for 5 min, reactions proceeded
with 30 cycles of denaturation, annealing and extension (94‡C, 30 s;
55‡C 30 s; and 72‡C 30 s). Extension times for fragments 232^1429
and 1^1429 were 4 min. PCR fragments were subcloned into the
pGreen Lantern Vector (GIBCO-BRL) using EcoR1 and Spe1 restric-
tion sites. nNOS-GFP fusion constructs (1^100-nNOS-GFP, 1^231-
nNOS-GFP, 101^231-nNOS-GFP, 232^1429-nNOS-GFP and FL-
nNOS-GFP) were con¢rmed by automated nucleotide sequencing.
2.5. Transfection of COS-7 cells
COS-7 cells were transfected with nNOS-GFP plasmids when ap-
proximately 70^80% con£uent using 3 Wg plasmid and 4 Wl Fugene-6
(Roche Biochemicals) according to the manufacturer’s procedure.
Cells were harvested 48 h after transfection by scraping into 250 Wl
of bu¡er A: 50 mM Tris^HCl pH 7.5, 1 mM EGTA, 1 mM EDTA,
1 mM DTT, and protease inhibitors: 100 Wg/ml phenylmethanesul-
fonyl £uoride, 20 Wg/ml leupeptin, 30 Wg/ml aprotinin,1 mM benza-
midine, 20 Wg/ml pepstatin and stored at 320‡C.
2.6. Preparation of C2C12 cell lysates
C2C12 myoblasts or di¡erentiating myotubes were prepared as de-
scribed above. On days 0, 2, 4, 6, 8, 10 and 12 of di¡erentiation, cells
in 60 mm culture dishes were scraped into 250 Wl of bu¡er A as
described above for COS-7 cells. Samples were kept frozen at
370‡C until used for nNOS expression analysis. In some experiments,
lysates from day 12 di¡erentiated C2C12 myotubes were extracted
with bu¡er A supplemented with either 0.3 M NaCl or 1% Triton
X-100. These extracts were then centrifuged at 100 000Ug for 30 min
at 4‡C. The pellets were resuspended in an equivalent volume of SDS^
PAGE sample bu¡er (250 Wl) and both supernatant and resuspended
pellet fractions were analyzed for distribution of nNOS in C2C12
myotube extracts. Control samples were extracted with bu¡er A alone
and fractionated by centrifugation as described above.
2.7. Expression and puri¢cation of K-syntrophin-GST
Human K-syntrophin subcloned into the EcoR1 restriction site of
pBluescript KSII (Stratagene, CA, USA) was a gift from Louis Kun-
kel. A 1.9 kb EcoR1/Xho1 cDNA fragment encoding the full length
human K-syntrophin was subcloned into the glutathione reductase
(GST) expression plasmid pGEX-2T (Amersham-Pharmacia, UK) us-
ing the same restriction sites. Expression of GST-human K-syntrophin
fusion protein in DH5K Escherichia coli cells was induced using 1 mM
IPTG for 3 h at 37‡C. Cells were collected (10 000Ug for 20 min) and
extracted by sonication 3U20 s into bu¡er A (see above). The cell
lysate was centrifuged at 10 000Ug for 15 min to remove membranes
and particulate material. The clear supernatant fraction was applied
to a 2 ml GST-Sepharose column (Amersham-Pharmacia) pre-equili-
brated with bu¡er A. The column resin was washed using 20 ml of
bu¡er A followed by 20 ml bu¡er A containing 0.5 M NaCl to re-
move unbound proteins. Puri¢ed GST-K-syntrophin protein was
eluted from the column with bu¡er A containing 10 mM glutathione
and stored at 320‡C.
2.8. Immunolocalization of nNOS in C2C12 myotubes
Coverslips containing myotubes were washed once with 2 ml of
10% PBS and then ¢xed with 1 ml 4% paraformaldehyde in PBS
for 20 min at room temperature. The coverslips were then washed
three times with PBS and the cells permeabilized for 15 min using
0.5% Triton X-100 in PBS, and blocked with 2% goat serum (Sigma,
USA) in PBS for 1 h. The coverslips were washed once with 2 ml PBS,
then overlaid and incubated overnight at 4‡C with 500 Wl of primary
antibody (anti-rabbit nNOS antibody raised against the N-terminal
231 amino acids of rat nNOS). Coverslips were washed four times
with PBS, and incubated with 300 Wl of secondary antibody, rhod-
amine goat anti-rabbit 2 mg/ml (Molecular Probes) at 1:200 in PBS
for 1 h in the dark at room temperature. Coverslips were washed with
water four times and inverted onto a glass slide containing one drop
of FluroGuard Antifade Reagent (Bio-Rad, CA, USA). The coverslip
was permanently ¢xed to the glass slide using nail polish.
2.9. Fluorescence imaging
Fluorescence imaging of transfected C2C12 myotubes with di¡erent
nNOS-GFP constructs was performed using a £uorescence micro-
scope described previously [15]. Fourteen bit £uorescence images
were acquired by a cooled CCD camera (Photometrics CCD200, Tuc-
son, AZ, USA) and BDS-Image software (Oncor, Gaithersburg, MD,
USA).
2.10. Western blotting and overlaying of nNOS-GFP proteins with
GST-K-syntrophin
Protein samples from C2C12 myoblasts, di¡erentiated C2C12 my-
otubes or transfected COS-7 cell extracts (20 Wl) were prepared in
SDS^PAGE sample bu¡er and loaded onto 10% SDS^polyacrylamide
gels and resolved for 2 h at 120 V and transferred onto nitrocellulose
membrane for immunoblot analysis for expression of nNOS or
nNOS-GFP expression using rabbit anti-nNOS (1:1000 dilution), a
gift from Bettie-Sue Masters, or mouse anti-GFP monoclonal primary
antibody (1:1000 dilution, Zymed Labs., CA, USA) respectively.
Antibody binding was visualized using enhanced chemiluminescence
(Amersham-Pharmacia, UK). To detect GST-K-syntrophin binding to
nNOS-GFP in COS-7 cell lysates, nitrocellulose ¢lters were prepared
as before and incubated overnight with GST-K-syntrophin (200 Wg/ml)
in 10 mM Tris^HCl pH 7.5, 100 mM NaCl, 0.05% Tween-20 (TBST)
containing 5% milk at 4‡C. The membranes were washed (3U5 min)
with TBST and incubated with mouse anti-GST monoclonal antibody
(Sigma, USA) at 1:1000 dilution for 1 h at room temperature. Mem-
branes were washed (3U5 min) and GST-K-syntrophin binding visu-
alized by enhanced chemiluminescence (Amersham-Pharmacia, UK).
3. Results
3.1. Expression of nNOS in di¡erentiating C2C12 myotubes
Immunoblot analysis of extracts from di¡erentiating C2C12
myoblasts shows that expression of nNOS increases signi¢-
cantly during di¡erentiation. In C2C12 myoblasts little if
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any nNOS is detected in cell extracts over a period of 10 days
in culture (Fig. 1A). In di¡erentiating C2C12 myotubes how-
ever, signi¢cant nNOS expression is observed by day 4 which
continues to increase to day 12 (Fig. 1B). Biochemical analysis
of subcellular localization of nNOS in fully di¡erentiated
C2C12 myotubes (day 12) shows an approximately equal dis-
tribution of nNOS between the soluble and insoluble fractions
(Fig. 1). This distribution is similar to our previous ¢ndings of
nNOS distribution in mouse skeletal muscle extracts [3]. A
biochemical characteristic of sarcolemmal bound skeletal
muscle nNOS is its solubility in bu¡ers containing high salt
and insolubility in bu¡ers containing Triton X-100 [2,3]. In
fully di¡erentiated C2C12 myotubes, the insoluble nNOS was
completely extracted with bu¡er containing 1 M NaCl and
not with bu¡er containing 1% Triton X-100 (Fig. 1C, lanes
2 and 3).
3.2. Localization of nNOS to the sarcolemma of C2C12
myotubes
Immunolocalization of endogenous nNOS in C2C12 myo-
tubes di¡erentiated for 12 days shows staining at the sarco-
lemma (Fig. 2A). Pre-immune serum shows no signi¢cant
staining, indicating that the £uorescence observed at the sar-
colemma of C2C12 myotubes in Fig. 2A is speci¢cally nNOS
(Fig. 2B). Localization of endogenous nNOS at the sarcolem-
ma is observed by day 5 of di¡erentiation (not shown). After
12 days of di¡erentiation, the C2C12 myotubes appeared mul-
ti-nucleated and twitched spontaneously in culture.
3.3. Full length nNOS-GFP localizes to the sarcolemma of
di¡erentiated C2C12 myotubes
In order to determine which domain(s) of nNOS were re-
quired for localization to the sarcolemma, GFP-tagged nNOS
constructs were prepared and transfected into C2C12 myo-
blasts. Expression and visualization of GFP-tagged nNOS
were monitored as di¡erentiation proceeded. In non-di¡eren-
tiating C2C12 myoblasts, expressed full length nNOS (FL-
Fig. 1. Expression of endogenous nNOS in di¡erentiating C2C12
myotubes. A: C2C12 myoblasts were grown in DMEM, 20% fetal
bovine serum, 100 units/ml penicillin, and 100 Wg/ml streptomycin
at 37‡C with 5% CO2. Cells were harvested in bu¡er A and sub-
jected to SDS^PAGE followed by Western blotting with anti-nNOS
Ab with puri¢ed nNOS as control (C). B: At day 2, myoblasts
maintained in DMEM containing 20% fetal bovine serum were
treated with DMEM containing 2% heat-inactivated horse serum,
10 Wg/ml insulin, and 10 Wg/ml transferrin to induce formation of
myotubes. C: C2C12 myotubes were harvested on day 12 and cen-
trifuged at 100 000Ug for 30 min to obtain the supernatant (S) and
pellet (P) fractions. Lane 1, cells harvested in bu¡er A; lane 2, in
bu¡er A with 1 M NaCl; and lane 3, in bu¡er A with 1% Triton
X-100.
Fig. 2. Immunostaining of C2C12 myoblasts and myotubes with
nNOS antibody. Day 12 di¡erentiated C2C12 myotubes (A) and
C2C12 myoblasts (B) were stained for endogenous nNOS. Sarcolem-
mal staining of nNOS is prominent in day 12 di¡erentiated myo-
tubes and not myoblasts.
Fig. 3. Fluorescence imaging of C2C12 myotubes and myoblasts
transfected with FL-nNOS-GFP. C2C12 myoblasts were transfected
with FL-nNOS-GFP (A, B and C) or pGreen Lantern Vector (D)
and di¡erentiated into myotubes (B, C and D). Fluorescence images
were acquired on day 12 in undi¡erentiated myoblasts (A), day 6
(B) or day 12 (C and D) of di¡erentiation. FL-nNOS-GFP is at the
sarcolemma in day 6 and day 12 di¡erentiated myotubes. GFP
alone does not localize to the sarcolemma in day 12 di¡erentiated
myotubes (D).
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nNOS-GFP) was observed as di¡use £uorescence throughout
the cytoplasm of the C2C12 myoblasts (Fig. 3A). However by
6 days fused myoblasts appeared multi-nucleated and sarco-
lemmal localization of FL-nNOS-GFP was apparent (Fig.
3B). After 12 days of di¡erentiation FL-nNOS-GFP was
bound predominantly to the sarcolemma (Fig. 3C). As a con-
trol, expression of GFP protein by itself in day 12 di¡erenti-
ated C2C12 myotubes resulted in di¡use £uorescence through-
out the myotube with no localization to the sarcolemma (Fig.
3D).
3.4. The N-terminus of nNOS localizes to the sarcolemma in
C2C12 myotubes
The £uorescence imaging results obtained in Figs. 2 and 3
showed that endogenous nNOS and FL-nNOS-GFP both lo-
calized to the sarcolemma in di¡erentiated C2C12 myotubes
consistent with localization of nNOS to the DGC in skeletal
muscle tissues. To determine whether or not the N-terminus
of nNOS was responsible for the localization, plasmid con-
structs were made which expressed fragments of the unique N-
terminus of nNOS. The GFP-tagged nNOS fragments en-
coded the whole N-terminal region of nNOS, 1^231-nNOS-
GFP; the PDZ domain of nNOS, 1^100-nNOS-GFP; and the
region containing the L-hairpin ¢nger loop, 101^231-nNOS-
GFP. A C-terminal GFP fusion construct was also prepared
that encoded the remaining regions of nNOS, 232^1429-
nNOS-GFP. These constructs were transfected into C2C12
myoblasts which were allowed to di¡erentiate for 12 days.
When C2C12 myotubes were fully di¡erentiated by day 12,
cells transfected with 1^231-nNOS-GFP (the unique N-termi-
nal 231 amino acids) localized to the sarcolemma, (Fig. 4A).
In C2C12 myotubes transfected with 232^1429-nNOS-GFP,
£uorescence was di¡use and spread throughout the myotube
indicating that there are no sarcolemmal localization determi-
nants in the C-terminal of nNOS (amino acids 232^1429; Fig.
4D).
To determine the structural motifs required for sarcolem-
mal binding, the PDZ domain and the L-hairpin ¢nger loop
were expressed independently as GFP fusion proteins. Cells
transfected with the 1^100-nNOS-GFP plasmid encoding the
PDZ domain of nNOS localized to the sarcolemma indicating
a direct nNOS PDZ domain interaction with the sarcolemma
of C2C12 myotubes (Fig. 4B). Cells transfected with the 101^
231-nNOS-GFP plasmid which expressed the L-hairpin ¢nger
loop also showed £uorescence at the sarcolemma (Fig. 4C).
Thus both the PDZ domain (amino acids 1^100) and the
region containing the L-hairpin ¢nger loop (amino acids
101^231) are independently su⁄cient for subcellular localiza-
tion of nNOS to the sarcolemma in C2C12 myotubes.
3.5. Binding of K-syntrophin to nNOS-GFP fusion proteins
Western immunoblot analysis of extracts of COS-7 cells
transfected with nNOS-GFP constructs demonstrated that
each construct expressed the expected size of nNOS-GFP fu-
sion protein (Fig. 5A). Identical samples were transferred to a
nitrocellulose membrane and subjected to GST-K-syntrophin
overlay analysis. Fig. 5B shows that GST-K-syntrophin binds
to the 1^231-nNOS-GFP and the 101^231-nNOS-GFP fusion
proteins. However, GST-K-syntrophin did not bind to 1^100-
nNOS-GFP which contains only the PDZ domain of nNOS.
It also did not bind the 232^1429-nNOS-GFP fusion protein.
Fig. 4. Fluorescence imaging of C2C12 myotubes transfected with
nNOS-GFP fusion constructs. C2C12 myotubes di¡erentiated for 12
days after transfecting myoblasts with 1^231-nNOS-GFP (PDZ do-
main plus L-hairpin ¢nger loop of nNOS) (A), 1^100-nNOS-GFP
(PDZ domain of nNOS) (B), 101^231-nNOS-GFP (L-hairpin ¢nger
loop of nNOS) (C), or 232^1429-nNOS-GFP (C-terminal portion of
nNOS) (D). Sarcolemmal localization is observed with nNOS-GFP
fragments containing the N-terminus (A, B and C) but not with the
C-terminal portion of nNOS.
Fig. 5. K-Syntrophin overlay of nNOS-GFP proteins. COS-7 cells
were transfected with plasmid constructs of pGreen Lantern Vector
(A), 1^100-nNOS-GFP (B), 1^231-nNOS-GFP (C), 101^231-nNOS-
GFP (D), and 232^1429-nNOS-GFP (E). Cells were harvested after
48 h, and extracts electrophoresed on 10% SDS^PAGE followed by
transfer to nitrocellulose membrane. Nitrocellulose membranes were
either immunoblotted with anti-nNOS (upper panel) or overlaid
with GST-K-syntrophin and probed with anti-GST (lower panel).
GST-K-syntrophin binds only to 1^231-nNOS-GFP (C) and 101^
231-nNOS-GFP (D) and not to the 1^100-nNOS-GFP (B) nor the
C-terminal nNOS 232^1429-nNOS-GFP.
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In control overlay experiments, puri¢ed GST did not bind to
any of the nNOS-GFP expressed proteins in COS-7 cell ly-
sates (data not shown).
4. Discussion
In the present study, we show that nNOS expression is
induced upon C2C12 myotube formation. The nNOS ex-
pressed in fully di¡erentiated C2C12 myotubes exhibited sim-
ilar properties to the nNOS isolated in skeletal muscles in
terms of cytosolic and insoluble sarcolemmal distribution [1^
3,5]. The major components of the DGC have been shown to
be present at the sarcolemma in fully di¡erentiated C2C12
myotubes [10,11,13,14]. FL-nNOS-GFP was also localized to
the sarcolemma in fully di¡erentiated C2C12 myotubes and
not in C2C12 myoblasts. However, in a recent report where
dystrophin and L-dystroglycan were found at the sarcolemma
of di¡erentiated C2C12 myotubes, nNOS was not, contrary to
the ¢ndings of this study [12]. The shorter di¡erentiation pe-
riod of the C2C12 myoblasts (5 days) in that study may have
accounted for the lack of nNOS localization at the sarcolem-
ma. The identical sarcolemmal localization of both endoge-
nous and FL-nNOS-GFP allowed us to address the question
as to which region(s) of nNOS was responsible for this local-
ization.
The association of nNOS with the DGC at the sarcolemma
is assumed to be mediated by interaction of the unique N-
terminal region of nNOS (residues 1^231) with the PDZ do-
main of K-syntrophin [6,7]. PDZ-mediated interactions of
most proteins occur through recognition of short consensus
COOH-terminal peptide motifs binding to the peptide binding
groove of the PDZ domain [16]. Other types of PDZ-mediated
interactions exist which include interactions between PDZ do-
mains of two or more di¡erent proteins. These interactions do
not involve the recognition of a COOH-terminal sequence by
a PDZ domain but instead require the full tertiary structure of
the interacting PDZ domains [6]. The PDZ^PDZ interaction
between nNOS and K-syntrophin is unique in that it involves
the binding of the L-hairpin ¢nger loop found downstream of
the nNOS PDZ domain located between residues 101^130 of
nNOS to the peptide binding groove in the PDZ domain of K-
syntrophin [9]. The result of this interaction is the formation
of a heterodimer between nNOS and K-syntrophin. The PDZ
domain of nNOS also interacts with PSD-95 in neuronal cells
forming a heterodimer [6]. In a recent report, the L-hairpin
¢nger loop without the nNOS PDZ domain was also shown
to bind to the PDZ domain PSD-95 [17]. Moreover, the L-
hairpin ¢nger loop forms a stable structure by itself. The bind-
ing of GST-K-syntrophin to residues 101^231 of nNOS and
not residues 1^100 of the PDZ domain of nNOS demonstrates
the speci¢c nature of the nNOS/K-syntrophin interaction.
These interactions of the L-hairpin ¢nger loop with K-syntro-
phin PDZ domain leave the peptide binding groove of the
nNOS PDZ domain available to interact with additional pro-
teins. The absence of GST-K-syntrophin binding to the PDZ
domain of nNOS is similar to the observation that nNOS
PDZ domain (residues 1^100) also does not bind to the
PDZ domain of the postsynaptic density protein-93 [18].
The biochemical studies of the N-terminal region of nNOS
binding to the PDZ domain of K-syntrophin suggest K-syn-
trophin is required for nNOS to be localized to the sarcolem-
ma [6,7]. This view is supported by the absence of nNOS
localization at the sarcolemma in skeletal muscles isolated
from mice with ablation of K-syntrophin [19]. In mice lacking
K-syntrophin, dystrophin and other components of the DGC
are present at the sarcolemma but nNOS is not [19]. In two
other reports however, sarcolemmal localization of nNOS was
absent despite K-syntrophin at the sarcolemma [9,20]. In one
case K-syntrophin was found at the sarcolemma of skeletal
muscle from transgenic mdx mice expressing only the C-ter-
minal 71 kDa of dystrophin or expressing dystrophin minus
the ‘rod-like’ spectrin motif [20]. However nNOS was not
detected at the sarcolemma in skeletal muscles from these
mice. In skeletal muscles from dystrobrevin-de¢cient mice,
K-syntrophin was also found at the sarcolemma but nNOS
was not [9]. K-Syntrophin therefore may be required but is
not su⁄cient for nNOS localization to the sarcolemma. We
show that 1^100-nNOS-GFP also binds to the sarcolemma in
di¡erentiated myotubes but does not bind to K-syntrophin.
Thus the PDZ domain of nNOS is probably binding to an-
other protein localized at the sarcolemma.
In this study, we show that the nNOS PDZ domain and the
L-hairpin ¢nger loop bind to the sarcolemma. In addition, the
L-hairpin ¢nger loop binds to K-syntrophin. Therefore it is
predicted that either the PDZ domain or the L-hairpin ¢nger
loop would confer high-a⁄nity binding of nNOS to the sar-
colemma in skeletal muscle. However, nNOS is not localized
to the sarcolemma in skeletal muscles from mice lacking K-
syntrophin. Conversely, in muscles from mice lacking dystro-
brevin, K-syntrophin is present at the sarcolemma but nNOS
is not. The di¡erence with our observations in C2C12 myo-
tubes and the results from genetically manipulated mouse
models indicate that the situation in the C2C12 myotube sys-
tem may not be identical to that in skeletal muscles in vivo.
Perhaps two di¡erent proteins binding to the PDZ and the L-
hairpin ¢nger loop respectively are required for nNOS local-
ization to the sarcolemma in skeletal muscle tissues.
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